Kimavi's video: What is Molnupiravir by DRIVE at Emory Merck and Ridgeback Biotherapeutics Rick Bright and Tam

Welcome to Kimavi Super Simple Educational Videos. What is Molnupiravir, by DRIVE at Emory, Merck and Ridgeback Biotherapeutics? Rick Bright and Tamiflu? Molnupiravir is an experimental Covid-19 drug that could be Tamiflu for the Covid 19 pandemic Only one antiviral has been authorized for use remdesivir from Gilead Sciences Inc., and it provides modest benefit in hospitalized patients Let's learn more What is Molnupiravir Molnupiravir is an experimental antiviral drug which is orally active and was developed for the treatment of influenza It is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, and exerts its antiviral action through introduction of copying errors during viral RNA replication Activity has also been demonstrated against coronaviruses including SARS, MERS and SARS-CoV-2. The drug was developed at Emory University by the university's drug innovation company, Drug Innovation Ventures at Emory It was then acquired by Miami-based company Ridgeback Biotherapeutics, who later partnered with Merck and Co. to develop the drug further Safety controversy? In April 2020, a whistleblower complaint by former Head of US Biomedical Advanced Research and Development Authority Rick Bright revealed concerns over providing funding for the further development of molnupiravir due to similar drugs having mutagenic or DNA damaging properties These claims were denied by George Painter, CEO of DRIVE, noting that toxicity studies on molnupiravir had been carried out Covid 19 Impact .... .... Thank you from Kimavi, Please visit us at Kimavi.Com for more Super Simple Educational videos